China Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein engineering and their mission to become a highly differentiated oncology biotech company, and Alphamab’s dual China-US development strategy in support…
Algeria Ipsen’s Guillaume Freneuil gives his take on the importance of the Algerian market to the global group. If we are investing right now in Algeria it is because we envisage further growth here to be able to serve patient needs 33 percent of Sales within Ipsen are now in…
IFPMA Across the month of January, we at PharmaBoardroom surveyed our executive readership on attitudes towards the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)’s new Code of Practice, effective January 1st, 2019. To download the Code click here and to read our exclusive interview with Melissa Barnes, the IFPMA’s ethics…
Algeria Click here to download the Healthcare & Life Sciences Review Algeria 2019 report. Algeria, Africa’s largest country by area, stands as a promising investment destination for the global life sciences industry, with a sizeable local market and a growing number of multinationals choosing to base their regional operations out…
Turkey Imports and exports in Turkish pharma between 2010 and 2017. Pharmaceutical exports grew to a total of USD 898 million in 2017. These charts show both the volume and value of imported and locally-produced drugs in the Turkish pharma market between 2010 and 2017. TL 13.33 billion (USD 2.57…
UK In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on the up, but just in case we were becoming immune to these warnings, the UK has dropped a big announcement that not only indicates the country’s commitment to the problem but also the imminent threat that…
Turkey Bucking a global trend for increased focus on outpatient and preventative care, Turkey is doubling down on hospital investment. Throughout many of the healthcare systems in North America and Europe, there is an increasing emphasis on outpatient and preventative care. In terms of health economics, governments see a great benefit in…
India Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output and drug inspectors. Improving the image of drug inspectors- will require investments in “infrastructure”. The key elements of this…
France The Top 20 pharma companies in France, ranked by total turnover at ex-manufacturer prices for 2018. Swiss giant Novartis is in first place with a EUR 2.6 billion turnover, a full 89 percent of which came from the retail market. In second place is local champion Sanofi with a turnover…
Mexico Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. In this article, Thompson outlines the country’s challenges to the healthcare system and the pharma…
Turkey Armağan Vurdu, general secretary of the Istanbul Minerals and Metals Exporters Association (IMMIB) highlights the strategic importance of the chemical and pharmaceutical sectors in Turkey’s exports. He underscores pharma’s role in Turkey’s ‘Vision 2023’ and explains how IMMIB is helping the sector increase its export potential. With our 29…
China In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit domestic generic firms hardest unless they adapt their business models. Big Pharma could also lose out as their off-patent originators…
See our Cookie Privacy Policy Here
